神经元特异性烯醇化酶对ECMO患者心肺复苏后神经学结局的预测价值
本研究在65例心肺复苏后接受静脉-动脉ECMO治疗的患者中,于24、48、72小时测量神经元特异性烯醇化酶(NSE),以住院期间最佳脑功能分类评分(CPC)评估神经学状态。排除最初24小时内死亡及最初24小时内清醒的患者。48小时NSE对不良神经学结局(CPC 4-5)的判别能力最佳,ROC曲线AUC为0.87,截断值70 μg/L。使用三个时间点的连续NSE测量时特异性最高。上述结果在64例外部验证队列中得到验证。作者结论认为,在ECMO患者中NSE可用于评估神经学结局,连续测量特异性最高,但需前瞻性数据集进一步研究验证。
要点
- 心肺复苏后接受ECMO治疗的患者中,48小时NSE对不良神经学结局的判别能力最佳,ROC曲线AUC为0.87,截断值为70 μg/L。
- 使用24、48、72小时三个时间点的连续NSE测量时特异性最高。
- 推导队列65例患者中,30天全因死亡率为47.7%,不良神经学结局(CPC评分4-5)发生率为30.7%。
- 上述结果在64例患者的外部验证队列中得到验证。
- 作者结论认为NSE可用于评估ECMO患者心肺复苏后的神经学结局,但需前瞻性数据集进一步研究验证。
适用人群与场景
- 心肺复苏后接受静脉-动脉ECMO治疗的患者。
- 排除最初24小时内死亡的患者。
- 排除最初24小时内清醒的患者。
诊断标准与关键阈值
- 神经学状态采用住院期间最佳脑功能分类评分(CPC)评估,不良神经学结局定义为CPC评分4-5。
- 48小时NSE预测不良神经学结局的ROC曲线AUC为0.87,截断值为70 μg/L。
处置流程与药物剂量
- 于心肺复苏后24、48、72小时测量NSE。
- 使用24、48、72小时三个时间点的连续NSE测量时特异性最高。
研究设计与关键结果
- 推导队列65例患者,30天全因死亡率为47.7%,不良神经学结局(CPC评分4-5)发生率为30.7%。
- 48小时NSE对不良神经学结局的判别能力最佳,ROC曲线AUC为0.87,截断值70 μg/L。
- 使用三个时间点的连续NSE测量时特异性最高。
- 结果在64例患者的外部验证队列中得到验证。
证据类型、等级与局限
- 证据类型:推导队列研究,含外部验证队列(推导队列65例,外部验证队列64例)。
- 局限:作者指出需前瞻性数据集进一步研究以验证这些发现。
对床旁实践的改变
- 作者结论认为,在心肺复苏后接受ECMO治疗的患者中,NSE可用于评估神经学结局,连续NSE测量时特异性最高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Neuron-specific-enolase (NSE) is frequently used to predict the neurologic outcome in persistently unconscious patients after cardiopulmonary resuscitation (CPR). However, its predictive value is unclear in the setting of veno-arterial extracorporeal membrane oxygenation therapy (ECMO). Aim of this project is to evaluate the predictive value of NSE in ECMO patients.
METHODS: NSE was measured after 24, 48, and 72 h in post-CPR ECMO patients. Neurologic status was evaluated using the best Cerebral Performance Categories Score (CPC) during the hospital stay. Patients who deceased within the first 24 h and patients who were awake during the first 24 h were excluded. ROC curves were calculated to assess the discriminative ability of single NSE measurements. Trajectories of serial NSE values were investigated using latent class mixed models.
RESULTS: The derivation cohort consisted of 65 patients, 30-day all-cause mortality was 47.7% and a poor neurological outcome with a CPC score of 4-5 was seen 30.7%. NSE measurement after 48 h showed the best discrimination for poor neurological outcome (AUC of 0.87 in the ROC curve; cut-off value of 70 μg/L). Specificity was highest if using serial NSE measurements at all three time points. These results could be validated in an external cohort of 64 patients.
CONCLUSION: In post-CPR patients on ECMO, NSE can be used to assess the neurologic outcome. Importantly, specificity was highest if using serial NSE measurements. Further research using prospective datasets is needed to verify these findings.
参考来源
- Schrage B, Rübsamen N, Becher PM, et al. Neuron-specific-enolase as a predictor of the neurologic outcome after cardiopulmonary resuscitation in patients on ECMO. Resuscitation. 2019. PMID: 30654013. doi:10.1016/j.resuscitation.2019.01.011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。